We support drug and product preclinical development with trusted GLP and non-GLP scientific services with in vitro and in vivo rodent/non-rodent models.
Bridging innovation and preclinical development to advance healthier products.
Our Mission
Advance
Advance
Advise
Advise
Innovate
Innovate
Our services and models5
Therapeutic areas
-
Cardiology
-
Immuno-oncology
-
Oncology
-
Neurology
-
Pneumology
-
Allergy
-
Dermatology
-
Gastro-enterology
-
Analgesia/Inflammation
-
Endocrinology
-
Heamatology
-
Nephrology
Key stats
93%
of reports delivered before deadlines
2000+
studies performed during the last 5 years
1972
First ERBC site established in Italy, then the second one in France in 1973.
6K+
sites with BSL1, BSL2 and BSL3 laboratories.
News
06 March 26
02 March 26
13 February 26
16 September 25
Events
Jun 26
Bologna, Italy
Sep 26
Montreal, Canada
Sep 26
Bilbao, Spain
Krakow, Poland
Need to create
a unique project?
BOOK A 10’ CALL
BOOK A 10’ CALL
Frequently
Asked
Questions
ERBC, a leading preclinical Contract Research Organization (CRO), provides a comprehensive range of preclinical services, including discovery, toxicology, safety pharmacology, pharmacokinetics, bioanalytics, and translational research together with innovated models such as avian-PDX and Non-Human Primates (NHP). These services are tailored to support the pharmaceutical, biotechnology, chemical, agro-chemical, cosmetic and medical device industries.
Our studies are run at Good Laboratory Practice (GLP) and Good Clinical Practices (GCP) facilities to ensure regulatory compliance and high-quality results.
Engaging with ERBC begins with a consultation with our alliance management directors to understand your specific needs, followed by a tailored proposal outlining study design, timelines, and costs.
Engaging with ERBC begins with a consultation with our alliance management directors to understand your specific needs, followed by a tailored proposal outlining study design, timelines, and costs. Yes, our expertise includes preparing comprehensive regulatory packages, such as SEND-compliant datasets, to support IND and NDA submissions.
We offer end-to-end support, from early-stage discovery through to clinical trial material manufacturing, ensuring seamless progression and adherence to timelines.
